Evotec SE
XETRA:EVT
Intrinsic Value
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. [ Read More ]
The intrinsic value of one EVT stock under the Base Case scenario is 23.199 EUR. Compared to the current market price of 9.525 EUR, Evotec SE is Undervalued by 59%.
Valuation Backtest
Evotec SE
Run backtest to discover the historical profit from buying and selling EVT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Evotec SE
Current Assets | 903.2m |
Cash & Short-Term Investments | 616.9m |
Receivables | 204.1m |
Other Current Assets | 82.2m |
Non-Current Assets | 1.3B |
Long-Term Investments | 142.1m |
PP&E | 806.6m |
Intangibles | 291.1m |
Other Non-Current Assets | 109.6m |
Current Liabilities | 464.6m |
Accounts Payable | 134.3m |
Other Current Liabilities | 330.3m |
Non-Current Liabilities | 668m |
Long-Term Debt | 477.1m |
Other Non-Current Liabilities | 190.9m |
Earnings Waterfall
Evotec SE
Revenue
|
781.4m
EUR
|
Cost of Revenue
|
-606.4m
EUR
|
Gross Profit
|
175.1m
EUR
|
Operating Expenses
|
-217.5m
EUR
|
Operating Income
|
-42.5m
EUR
|
Other Expenses
|
-41.4m
EUR
|
Net Income
|
-83.9m
EUR
|
Free Cash Flow Analysis
Evotec SE
EVT Profitability Score
Profitability Due Diligence
Evotec SE's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Evotec SE's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
EVT Solvency Score
Solvency Due Diligence
Evotec SE's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Evotec SE's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EVT Price Targets Summary
Evotec SE
According to Wall Street analysts, the average 1-year price target for EVT is 25.618 EUR with a low forecast of 10.504 EUR and a high forecast of 52.5 EUR.
Shareholder Return
EVT Price
Evotec SE
Average Annual Return | 1.72% |
Standard Deviation of Annual Returns | 45.02% |
Max Drawdown | -80% |
Market Capitalization | 1.7B EUR |
Shares Outstanding | 176 935 700 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,521 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one EVT stock under the Base Case scenario is 23.199 EUR.
Compared to the current market price of 9.525 EUR, Evotec SE is Undervalued by 59%.